Inogen Inc (INGN) Drops 5.66% on February 05

Equities Staff  |

Inogen Inc (INGN) was one of the Russell 2000's biggest losers for Friday February 05 as the stock slid 5.66% to $31.16, a loss of $-1.87 per share. Starting at an opening price of $32.85 a share, the stock traded between $30.62 and $34.06 over the course of the trading day. Volume was 142,275 shares over 1,095 trades, against an average daily volume of 261,892 shares and a total float of 19.65 million.

The losses send Inogen Inc down to a market cap of $612.36 million. In the last year, Inogen Inc has traded between $55.98 and $29.33, and its 50-day SMA is currently $38.17 and 200-day SMA is $42.50.

The stock has a P/E Ratio of 80.2.

Inogen Inc is a medical technology company that develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Inogen Inc is based out of Goleta, CA and has some 411 employees. Its CEO is Raymond Huggenberger.

For a complete fundamental analysis analysis of Inogen Inc, check out’s Stock Valuation Analysis report for INGN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…